Brixton Biosciences Adds Leaders Ahead of Reneurx Launch
Cambridge, Massachusetts, August 18, 2026 Brixton Biosciences has strengthened its Board of Directors with the appointment of three experienced...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Cambridge, Massachusetts, August 18, 2026 Brixton Biosciences has strengthened its Board of Directors with the appointment of three experienced...
SAN DIEGO, April 30, 2026 Contineum Therapeutics, Inc. announced positive topline results from its Phase 1b clinical trial of...
INDIANAPOLIS, December 11, 2025 — Eli Lilly and Company announced positive topline results from the Phase 3 TRIUMPH-4 trial,...
